JP2023544294A5 - - Google Patents
Info
- Publication number
- JP2023544294A5 JP2023544294A5 JP2023519252A JP2023519252A JP2023544294A5 JP 2023544294 A5 JP2023544294 A5 JP 2023544294A5 JP 2023519252 A JP2023519252 A JP 2023519252A JP 2023519252 A JP2023519252 A JP 2023519252A JP 2023544294 A5 JP2023544294 A5 JP 2023544294A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- sequence shown
- cdr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2020/118320 | 2020-09-28 | ||
| CN2020118320 | 2020-09-28 | ||
| PCT/CN2021/121314 WO2022063316A1 (en) | 2020-09-28 | 2021-09-28 | Anti-cd47 antibodies and methods of use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023544294A JP2023544294A (ja) | 2023-10-23 |
| JP2023544294A5 true JP2023544294A5 (enExample) | 2024-10-07 |
| JP7820364B2 JP7820364B2 (ja) | 2026-02-25 |
Family
ID=80844512
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023519252A Active JP7820364B2 (ja) | 2020-09-28 | 2021-09-28 | 抗ｃｄ４７抗体及び使用方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US12630630B2 (enExample) |
| EP (1) | EP4217397A4 (enExample) |
| JP (1) | JP7820364B2 (enExample) |
| KR (1) | KR20230079393A (enExample) |
| CN (1) | CN116323675A (enExample) |
| AU (1) | AU2021346729A1 (enExample) |
| CA (1) | CA3191835A1 (enExample) |
| WO (1) | WO2022063316A1 (enExample) |
| ZA (1) | ZA202304167B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102757518B1 (ko) * | 2020-12-07 | 2025-01-21 | (주)이노베이션바이오 | Cd47에 특이적인 항체 및 이의 용도 |
| EP4319796A4 (en) | 2021-12-21 | 2025-07-23 | Fbd Biologics Ltd | MODIFIED SIRPalpha VARIANTS AND METHODS OF USE THEREOF |
| CN120584133A (zh) * | 2022-12-29 | 2025-09-02 | 上海复宏汉霖生物技术股份有限公司 | 抗cd47抗体及使用方法 |
| CN120693350A (zh) * | 2022-12-29 | 2025-09-23 | 上海复宏汉霖生物技术股份有限公司 | 抗pdl1抗体、多特异性抗体及使用方法 |
| WO2024245380A1 (en) | 2023-05-31 | 2024-12-05 | Fbd Biologics Limited | Cd47/pd-l1-targeting protein complex and methods of use thereof |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20190112374A1 (en) * | 2010-05-14 | 2019-04-18 | The Board Of Trustees Of The Leland Stanford Junior University | Humanized and chimeric monoclonal antibodies to cd47 |
| RU2693078C2 (ru) | 2012-12-03 | 2019-07-01 | Новиммун С.А. | Анти-cd47 антитела и способы их применения |
| CA3011097C (en) * | 2016-01-11 | 2022-12-20 | Forty Seven, Inc. | Humanized, mouse or chimeric anti-cd47 monoclonal antibodies |
| WO2017196793A1 (en) * | 2016-05-09 | 2017-11-16 | Celgene Corporation | Cd47 antibodies and methods of use thereof |
| CN106117354B (zh) * | 2016-06-24 | 2020-01-14 | 安徽未名细胞治疗有限公司 | 一种全人源抗CD47的全分子IgG抗体及其应用 |
| EP3532497B1 (en) * | 2016-10-26 | 2024-07-24 | The Board of Trustees of the Leland Stanford Junior University | Modified immunoglobulin hinge regions to reduce hemagglutination |
| EA039662B1 (ru) * | 2017-10-03 | 2022-02-24 | Закрытое Акционерное Общество "Биокад" | Антитела, специфичные к cd47 и pd-l1 |
| CN111629754B (zh) * | 2018-01-24 | 2023-10-20 | 南京传奇生物科技有限公司 | 不引起显著红血细胞凝集的抗cd47抗体 |
| CN111087470B (zh) * | 2020-01-19 | 2022-05-10 | 中国人民解放军第四军医大学 | 一种抗人CD47单克隆抗体7G4mAb及其应用 |
-
2021
- 2021-09-28 KR KR1020237013292A patent/KR20230079393A/ko active Pending
- 2021-09-28 CA CA3191835A patent/CA3191835A1/en active Pending
- 2021-09-28 WO PCT/CN2021/121314 patent/WO2022063316A1/en not_active Ceased
- 2021-09-28 EP EP21871685.0A patent/EP4217397A4/en active Pending
- 2021-09-28 JP JP2023519252A patent/JP7820364B2/ja active Active
- 2021-09-28 AU AU2021346729A patent/AU2021346729A1/en active Pending
- 2021-09-28 CN CN202180065682.2A patent/CN116323675A/zh active Pending
-
2023
- 2023-03-24 US US18/189,998 patent/US12630630B2/en active Active
- 2023-04-05 ZA ZA2023/04167A patent/ZA202304167B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN115052893A (zh) | 抗tigit抗体和使用方法 | |
| CN111148761B (zh) | 多特异性抗体及其制备和使用方法 | |
| JP7682789B2 (ja) | Ｂ７－Ｈ３のＩｇＶドメインに対するモノクローナル抗体及びその使用 | |
| JP7701911B2 (ja) | Ｃｅａｃａｍ５およびｃｄ３に対する二特異性抗体 | |
| US20230391882A1 (en) | Combination treatment | |
| JP7854121B2 (ja) | 微小ガイダンス及びナビゲーションコントロール（ｍｉｎｉＧＮＣ）抗体様タンパク質、その製造方法及び使用方法 | |
| JP7399852B2 (ja) | 多重特異性抗体とその作製及び使用方法 | |
| JP2021534802A5 (enExample) | ||
| AU2018336520B2 (en) | Novel anti-CD19 antibodies | |
| US20250034273A1 (en) | Composition of multispecific antibodies targeting cadherin-17-expressing tumors and method of making and using thereof | |
| JP2023537002A5 (enExample) | ||
| JP2024532482A5 (enExample) | ||
| JP7731979B2 (ja) | 特異性が増強した二重特異性抗体（ｓｅｂａ） | |
| CN114786720B (zh) | TriAx抗体的组合物及其制备和使用方法 | |
| KR20240164815A (ko) | 항-tigit/항-pvrig 이중특이적 항체, 이의 약제학적 조성물 및 이의 용도 | |
| JP2024515560A5 (enExample) | ||
| JP2023516945A5 (enExample) | ||
| IL321677A (en) | Anti-PDL1 antibodies, multispecific antibodies, and methods of use | |
| JP2022536370A5 (enExample) | ||
| RU2025120809A (ru) | Антитела против cd47 и способы их применения | |
| JP2023553861A5 (enExample) | ||
| Kafil et al. | Immunotargeting and therapy of cancer by advanced multivalence antibody scaffolds | |
| JP2025501522A5 (ja) | 抗体、免疫コンジュゲート、抗原認識受容体、免疫応答性細胞、医薬組成物、核酸、ベクター、宿主細胞、方法、及びキット | |
| RU2025109828A (ru) | Антитела против b7h3 и способы их применения | |
| RU2025120667A (ru) | Антитела против pdl1 и способы их применения |